CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 59 enrolled / 59 target
Drug / intervention
Zoledronic Acid +1 moredrug
Likely dose
Zoledronic Acid 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04742010
NCT04742010Phase 2CompletedOn Track (0.9/mo)Completion was 32mo ago
CompareCT.gov

Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)

Stinus Gadegaard Hansen·interventional·Posted Feb 5, 2021·Updated Jun 1, 2026

In Brief

A Phase 2 clinical trial evaluating Zoledronic Acid and Placebo for Bone Loss and 2 related conditions. Completed, enrolled 59 participants across 1 site.

Detailed Summary

In a randomised placebo-controlled trial assess effects of zoledronic acid for prevention of bone and muscle loss after bariatric surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Loss, Muscle Atrophy, Bariatric Surgery
CountriesDenmark
CollaboratorsResearch Unit of Health Sciences, Hospital of South West Jutland, University of Southern Denmark, OPEN - Odense Patient data Explorative Network, The University of Southern Denmark, Odense, Denmark, Department of Radiology and Nuclear Medicine, Hospital of Southwest Jutland, 6700 Esbjerg, Denmark, Odense University Hospital

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 5, 2021
Enrollment StartFeb 20, 2021
Primary CompletionNov 1, 2023
Study CompletionAug 12, 2024
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.4 years ago

Arms & Interventions

Zoledronic Acidexperimental

Active treatment

Drug: Zoledronic Acid
Placeboplacebo_comparator

Placebo

Drug: Placebo

Interventions

Zoledronic Aciddrug

* A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted) * Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo) * Administration: slow intravenous infusion with a duration of at least 15 minutes

Placebodrug

as above